<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294836</url>
  </required_header>
  <id_info>
    <org_study_id>IX-023435</org_study_id>
    <nct_id>NCT04294836</nct_id>
  </id_info>
  <brief_title>Curcumin in Advanced Cervical Cancer</brief_title>
  <official_title>Randomized Phase II Clinical Trial of Oral Turmeric Supplementation in Patients With Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Cancerologia, Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Cancerologia, Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the efficacy and safety of turmeric in the treatment of patients with advanced
      cervical cancer. Efficacy will be determined through radiological and histopathological
      criteria through the rate of response to treatment, duration of response, the rate of
      objective response and disease control, as well as overall survival and disease-free
      survival. The safety of therapy will be evaluated according to the Common Terminology
      Criteria for Adverse Events (CTCAE) classification
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo-controlled phase II clinical trial will be developed in patients with advanced
      cervical cancer who have an indication for radiotherapy. Those who accept to participate will
      receive the standard treatment with established chemo-radiation and will be randomized in two
      arms, the experimental will receive 500mg of the commercial presentation (curcugreen) c / 6h
      VO x 16 weeks and the control arm will receive placebo. The operative hypotheses are: the
      addition of curcumin to the treatment improves the cumulative probability of 3-year overall
      survival by 20% and improves the treatment response rate. The statistical analysis will
      include a Cox proportional hazards model and the results of the groups will be compared with
      the Student's T-test or ANOVA. This research hopes to collect tissue samples for future
      research that allows the identification of predictive biomarkers and disease prognoses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II clinical trial, randomized and placebo controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Compare overall survival and progression free survival</measure>
    <time_frame>3 yr</time_frame>
    <description>Global survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the objective response rate using RECIST radiological criteria</measure>
    <time_frame>1 yr</time_frame>
    <description>Objective response by RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the disease control rate</measure>
    <time_frame>1 yr</time_frame>
    <description>Disease control rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the safety of research therapy by classifying Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>1 yr</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cervical Cancer, Stage IIB</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Curcugreen (BCM95) 2000mg daily (each 6h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Chemotherapy (cisplatin) plus concomitant radiation therapy (teletherapy + high or low rate brachytherapy) + Placebo Capsules 500mg 2000mg daily (each 6h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>BCM-95® (CURCUGREEN®) is a 100 percent pure extract of turmeric with enhanced bio-availability and bio-efficacy. Its powerful health-promoting benefits are derived from the colorful and aromatic qualities of the Indian spice</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>PLACEBO Capsules 500mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Women aged 18 years or older

          -  Voluntary acceptance of participation and signing of informed consent

          -  Radiotherapy indication

          -  Histological confirmation of squamous cervical cancer or histologically confirmed
             adenocarcinoma

          -  Stage IIB - VAT

          -  Chemo-radiation indication with Cisplatin, Cisplatin/fluorouracil, Carboplatin (if
             cisplatin intolerant)

          -  ECOG equal to or less than 1 and a Karnofsky index equal to or greater than 70%.

        Exclusion Criteria:

          -  Being pregnant or breastfeeding

          -  Presence of second concomitant neoplasia

          -  Any previous surgical, radiotherapy or chemotherapy treatment.

          -  Diagnosis of invasive recurrent carcinoma of the cervix

          -  Receive anticoagulant therapy

          -  Receive immunosuppression therapy

          -  Presence of coagulation disorders, such as platelet count less than 100,000 at the
             time of the joint evaluation, absolute neutrophil count less than 1,500 / ml

          -  Presence of signs of systemic infection

          -  Renal failure, creatinine clearance less than 45 ml/min confirmed with glomerular
             filtration less than 45 ml / min; evidence of unilateral renal exclusion

          -  Patients with uncontrolled metabolic disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose A Carreño, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Cancerología</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rene Pareja, Md</last_name>
    <phone>+5714320160</phone>
    <phone_ext>5958</phone_ext>
    <email>ensayosclinicos@cancer.gov.co</email>
  </overall_contact>
  <results_reference>
    <citation>Saadipoor A, Razzaghdoust A, Simforoosh N, Mahdavi A, Bakhshandeh M, Moghadam M, Abdollahi H, Mofid B. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy. Phytother Res. 2019 Feb;33(2):370-378. doi: 10.1002/ptr.6230. Epub 2018 Nov 14.</citation>
    <PMID>30427093</PMID>
  </results_reference>
  <results_reference>
    <citation>Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol. 2008 May;73(5):1491-501. doi: 10.1124/mol.107.043554. Epub 2008 Feb 5.</citation>
    <PMID>18252805</PMID>
  </results_reference>
  <results_reference>
    <citation>Javvadi P, Hertan L, Kosoff R, Datta T, Kolev J, Mick R, Tuttle SW, Koumenis C. Thioredoxin reductase-1 mediates curcumin-induced radiosensitization of squamous carcinoma cells. Cancer Res. 2010 Mar 1;70(5):1941-50. doi: 10.1158/0008-5472.CAN-09-3025. Epub 2010 Feb 16.</citation>
    <PMID>20160040</PMID>
  </results_reference>
  <results_reference>
    <citation>Hejazi J, Rastmanesh R, Taleban FA, Molana SH, Hejazi E, Ehtejab G, Hara N. Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study. Nutr Cancer. 2016;68(1):77-85. doi: 10.1080/01635581.2016.1115527. Epub 2016 Jan 15.</citation>
    <PMID>26771294</PMID>
  </results_reference>
  <results_reference>
    <citation>Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katanasaka Y, Kakeya H, Fujita M, Hasegawa K, Morimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011;34(5):660-5.</citation>
    <PMID>21532153</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaman MS, Chauhan N, Yallapu MM, Gara RK, Maher DM, Kumari S, Sikander M, Khan S, Zafar N, Jaggi M, Chauhan SC. Curcumin Nanoformulation for Cervical Cancer Treatment. Sci Rep. 2016 Feb 3;6:20051. doi: 10.1038/srep20051.</citation>
    <PMID>26837852</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-9. doi: 10.1158/1078-0432.CCR-08-0024.</citation>
    <PMID>18628464</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>curcumin</keyword>
  <keyword>natural antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

